AbbVie’s Humira is the first to receive FDA approval for fingernail psoriasis

Biosimilar News

Today, AbbVie announced that the F.D.A. approved the inclusion of moderate to severe fingernail psoriasis data in the HUMIRA® (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. Fingernail psoriasis affects half of all psoriasis patients and HUMIRA is now the first-and-only biologic treatment with data on fingernail psoriasis in its U.S. prescribing information.

Download PDF

Comments are closed.